Free Trial

Biomerica (BMRA) Competitors

Biomerica logo
$2.96 +0.05 (+1.72%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$2.91 -0.05 (-1.69%)
As of 10/24/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BMRA vs. ANVS, XCUR, AKTX, KZR, RNTX, IMA, SONN, CVKD, LNAI, and DARE

Should you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Annovis Bio (ANVS), Exicure (XCUR), Akari Therapeutics (AKTX), Kezar Life Sciences (KZR), Rein Therapeutics (RNTX), ImageneBio (IMA), Sonnet BioTherapeutics (SONN), Cadrenal Therapeutics (CVKD), Lunai Bioworks (LNAI), and Dare Bioscience (DARE). These companies are all part of the "pharmaceutical products" industry.

Biomerica vs. Its Competitors

Annovis Bio (NYSE:ANVS) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Annovis Bio currently has a consensus target price of $13.50, suggesting a potential upside of 560.15%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than Biomerica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Annovis Bio
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Biomerica
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Annovis Bio has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500.

Biomerica has higher revenue and earnings than Annovis Bio. Biomerica is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Annovis BioN/AN/A-$24.59M-$2.04-1.00
Biomerica$4.88M1.79-$4.97M-$0.96-3.08

Annovis Bio has a net margin of 0.00% compared to Biomerica's net margin of -74.84%. Biomerica's return on equity of -73.44% beat Annovis Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Annovis BioN/A -206.01% -158.26%
Biomerica -74.84%-73.44%-53.26%

In the previous week, Biomerica had 1 more articles in the media than Annovis Bio. MarketBeat recorded 2 mentions for Biomerica and 1 mentions for Annovis Bio. Biomerica's average media sentiment score of 0.95 beat Annovis Bio's score of 0.00 indicating that Biomerica is being referred to more favorably in the news media.

Company Overall Sentiment
Annovis Bio Neutral
Biomerica Positive

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 22.3% of Biomerica shares are held by institutional investors. 20.8% of Annovis Bio shares are held by company insiders. Comparatively, 15.0% of Biomerica shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Biomerica beats Annovis Bio on 8 of the 15 factors compared between the two stocks.

Get Biomerica News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMRA vs. The Competition

MetricBiomericaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$8.58M$2.97B$6.24B$10.65B
Dividend YieldN/A57.75%5.71%4.82%
P/E Ratio-3.0826.3230.6130.44
Price / Sales1.79782.63596.73191.77
Price / CashN/A168.3237.0161.44
Price / Book1.695.6512.036.60
Net Income-$4.97M$33.06M$3.32B$276.82M
7 Day Performance-0.67%3.16%1.89%2.55%
1 Month Performance5.71%8.14%7.71%3.76%
1 Year Performance25.42%-2.49%56.33%33.04%

Biomerica Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMRA
Biomerica
0.8113 of 5 stars
$2.96
+1.7%
N/A+24.3%$8.58M$4.88M-3.0860Short Interest ↓
ANVS
Annovis Bio
2.5659 of 5 stars
$1.68
+1.2%
$17.33
+931.7%
-77.5%$32.74MN/A-0.823Analyst Forecast
Gap Down
XCUR
Exicure
1.7476 of 5 stars
$5.10
-0.8%
N/A+114.6%$32.22MN/A-1.3150Gap Up
AKTX
Akari Therapeutics
2.8723 of 5 stars
$0.98
+4.0%
$3.30
+236.7%
-67.4%$31.97MN/A0.009Analyst Forecast
Short Interest ↑
KZR
Kezar Life Sciences
3.0013 of 5 stars
$4.33
+0.9%
$9.00
+107.9%
-23.2%$31.70M$7M-0.4560Gap Down
High Trading Volume
RNTX
Rein Therapeutics
3.2156 of 5 stars
$1.34
+1.5%
$10.00
+646.3%
N/A$31.23MN/A-0.509Gap Up
IMA
ImageneBio
3.661 of 5 stars
$7.64
-0.7%
$35.50
+364.7%
-61.0%$30.64M$9.16M-0.9970News Coverage
Analyst Forecast
Gap Up
SONN
Sonnet BioTherapeutics
2.2574 of 5 stars
$4.31
-1.4%
$20.00
+364.0%
-21.6%$29.44M$20K0.0010News Coverage
CVKD
Cadrenal Therapeutics
3.2644 of 5 stars
$14.10
+0.8%
$32.00
+127.0%
-15.7%$28.91MN/A-1.594Analyst Forecast
LNAI
Lunai Bioworks
N/A$1.22
+5.2%
N/AN/A$28.28MN/A-0.1620
DARE
Dare Bioscience
2.3515 of 5 stars
$2.06
-2.8%
$10.00
+385.4%
-39.7%$27.77M$10K-0.9630Analyst Forecast

Related Companies and Tools


This page (NASDAQ:BMRA) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners